Affiliation:
1. Clinical Haematology St Vincent's Hospital Melbourne Melbourne Victoria Australia
2. Cellular Therapy Laboratory St Vincent's Hospital Melbourne Melbourne Victoria Australia
3. Apheresis Unit St Vincent's Hospital Melbourne Melbourne Victoria Australia
Abstract
AbstractBackgroundBortezomib, lenalidomide and dexamethasone (VRd) is now the standard‐of‐care induction therapy for newly diagnosed transplant‐eligible multiple myeloma patients, replacing bortezomib, cyclophosphamide and dexamethasone (VCD) therapy. Lenalidomide can negatively impact stem cell yield because of its myelosuppressive effects, although studies have shown that the latter can be overcome with the use of cyclophosphamide for peripheral blood stem cell (PBSC) mobilisation.Aims and MethodsTo investigate whether lenalidomide impacts on PBSC mobilisation and to evaluate the optimal mobilisation strategy post VRd induction, we performed a retrospective review of 56 myeloma patients at a single centre who had PBSC mobilisation between January 2019 and March 2021 and compared three cohorts: (i) VCD induction; mobilisation with granulocyte colony‐stimulating factor (G‐CSF) alone (n = 23); (ii) four cycles VRd induction; mobilisation with G‐CSF and cyclophosphamide (G‐CSF + Cyclo) (n = 20); and (iii) three cycles VRd induction; mobilisation with G‐CSF alone (n = 13).ResultsThere was no difference in the mean total CD34 count between VCD and VRd patients who had G‐CSF mobilisation (6.27 × 106/kg vs 5.50 × 106/kg, P > 0.99). VRd patients mobilised with G‐CSF + Cyclo achieved higher mean total CD34 counts compared with G‐CSF alone (8.89 × 106/kg vs 5.50 × 106/kg, P = 0.04). The majority of VRd patients who had G‐CSF + Cyclo (19 of 20; 95%) collected sufficient cells for two or more autologous stem cell transplants (ASCTs), regardless of whether this was required, compared with eight of 13 (62%) VRd patients who had G‐CSF alone.ConclusionWe conclude that successful PBSC mobilisation for at least one ASCT is possible after three cycles of VRd induction using G‐CSF alone. The upfront use of a cyclophosphamide‐based mobilisation strategy has a role in patients who have had VRd induction, where the aim is to collect enough stem cells for two or more ASCTs.